Plandaí Biotechnology's Upcoming Clinical Trial Could Strengthen Case for Phytofare in Treatment of Diabetes
May 18 2017 - 9:00AM
Marketwired
Plandaí Biotechnology's Upcoming Clinical Trial Could Strengthen
Case for Phytofare in Treatment of Diabetes
NEW YORK, NY-(Marketwired - May 18, 2017) - Plandaí
Biotechnology (OTCQB: PLPL) announced that it will conduct a human
clinical trial to study the effectiveness of using its highly
bioavailable green tea extract, Phytofare® Catechin Complex, to
regulate blood glucose levels in type 2 diabetics. If the positive
data that was recently published in the Journal of Human Nutrition
and Dietetics is any indicator, Plandaí should expect to receive
its own positive data. The two studies could complement one
another, and Plandaí's study could further strengthen the case for
using green tea catechins in improving the health of type 2
diabetics.
According to an industry report, the market for diabetes drugs
alone was valued at $30.95 billion in 2016, and it's expected to
grow at an exponential rate and become a $44.53 billion market by
2021, at a CAGR of about 7.5%.
Obviously Plandaí would like to carve out its own space in this
industry, and with a recently published study showing success with
a green tea supplement that only contained 1 of the tea plant's 8
catechins, Plandaí has to feel pretty confident it can produce even
better data given it can deliver all 8 catechins with its
Phytofare® extract.
Catechins are known as antioxidants, and antioxidants protect
the body from free radicals that are thought to play a role in
everything from heart disease to cancer. Catechins are found in the
greatest abundance in the leaves of the tea plant.
And we already know that Plandaí produces a product (Phytofare®)
that contains all 8 of the catechins found in the tea plant. But,
more importantly, Plandaí's product has proven in human clinical
trials that it can deliver 10 times more of the catechins into the
bloodstream and keep those antioxidants there at therapeutic levels
for more than 24 hours.
Now, let's fast forward to the data from a study that was just
published in the Journal of Human Nutrition and Dietetics and how
Plandaí can add to that data with its clinical trial in diabetes.
In that clinical trial, over 400 pregnant women, all of whom were
in their third trimester and were diagnosed with gestational
diabetes mellitus or "GDM," participated in investigating the
effects of the catechin "epigallocatechin 3-gallate" (EGCG) on GDM
in terms of both maternal and neonatal treatment outcomes.
Data from the study suggests that mothers with GDM, who were
given EGCG as a supplement during the third trimester of their
pregnancy, had significantly improved maternal diabetic parameters,
and fewer cases of neonatal complications, compared to similar
women given a placebo supplement.
One of the trial's authors, H. Zhang, said of the study, "Our
current clinical trial is the first to report the potential
therapeutic value of the natural compound EGCG in GDM, which is
able to both alleviate maternal diabetic symptoms and reduce the
incidence of neonatal complications."
A point that we can't emphasize enough from the GDM study that
could benefit Plandaí greatly is that participants were given a
supplement that contained only 1 of the 8 catechins, and we don't
even know how bioavailable the supplement was. During Plandaí's
clinical trial however, participants will be given Phytofare®,
which we know will deliver all 8 catechins into the bloodstream of
each participant in the study. So we expect that Plandaí's data
could be extremely positive and further strengthen the research
done in the GDM study.
Given how potent Phytofare® is, and how Plandaí is able to
enhance the already highly bioavailable extract even more by
entrapping it in liposomes, positive data from Plandaí's upcoming
clinical trial in type 2 diabetes could thrust the company into the
conversation, and become a real solution for how we're
treating/managing type 2 diabetes worldwide.
About Stock Market Media Group
Stock Market Media Group is a Content Development IR firm
offering a platform for corporate stories to unfold in the media
with research reports, corporate videos, CEO interviews and feature
news articles.
We may from time to time include our own opinions about our
featured companies, their businesses, markets and opportunities.
Any opinions we may offer are solely our own, and are made in
reliance upon our rights under the First Amendment to the U.S.
Constitution, and are provided solely for the general opinionated
discussion of our readers and viewers. Our opinions should not be
considered to be complete, precise, accurate, or current investment
advice, or construed or interpreted as research. Any investment
decisions you may make concerning any company are solely your
responsibility based on your own due diligence. Our publications
are provided only as an informational aid. We encourage you to
invest carefully and read the investor information available at the
web site of the U.S. Securities and Exchange Commission at:
http://www.sec.gov. We also recommend as a general rule, that
before investing in any securities you consult with a professional
financial planner or advisor, and you should conduct a complete and
independent investigation before investing in any security after
prudent consideration of all pertinent risks.
We are not a registered broker, dealer, analyst, or adviser. We
hold no investment licenses and may not sell, offer to sell or
offer to buy any security. Our publications are not a
recommendation to buy or sell a security.
Section 17(b) of the 1933 Securities and Exchange Act requires
publishers who distribute information about publicly traded
securities for compensation, to disclose who paid them, the amount,
and the type of payment. In order to be in full compliance with the
Securities Act of 1933, Section 17(b), we are disclosing that SMMG
is compensated $5,000 per month by Plandai Biotechnology for
content development. Neither SMMG nor anyone associated with it
owns shares in PLPL.
For more information: www.stockmarketmediagroup.com.
Contact: Stock Market Media Group
info@stockmarketmediagroup.com
Plandai Biotechnology (PK) (USOTC:PLPL)
Historical Stock Chart
From Oct 2024 to Nov 2024
Plandai Biotechnology (PK) (USOTC:PLPL)
Historical Stock Chart
From Nov 2023 to Nov 2024
